Daniela Matei - Publications

Affiliations: 
Biochemistry and Molecular Biology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Molecular Biology, Oncology

88 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner EJ, Wei J, Ji Y, Li J, Tan Y, Davuluri RV, Peter ME, Cheng JX, Matei D. Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis. Cancer Research. PMID 33172933 DOI: 10.1158/0008-5472.CAN-20-1488  0.6
2020 Li Z, An R, Swetzig WM, Kanis M, Nwani N, Turek J, Matei D, Nolte D. Intracellular optical doppler phenotypes of chemosensitivity in human epithelial ovarian cancer. Scientific Reports. 10: 17354. PMID 33060663 DOI: 10.1038/s41598-020-74336-x  0.52
2019 Cardenas H, Jiang G, Thomes Pepin J, Parker JB, Condello S, Nephew KP, Nakshatri H, Chakravarti D, Liu Y, Matei D. Interferon-γ signaling is associated with loss-of-function mutations in high grade serous ovarian cancer. Npj Precision Oncology. 3: 32. PMID 31840082 DOI: 10.1038/s41698-019-0103-4  0.6
2019 Sima LE, Yakubov B, Zhang S, Condello S, Grigorescu AA, Nwani N, Chen L, Schiltz GE, Arvanitis C, Zhang ZY, Matei D. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin. Molecular Cancer Therapeutics. PMID 31015308 DOI: 10.1158/1535-7163.Mct-18-1148  0.6
2019 Nwani NG, Condello S, Wang Y, Swetzig WM, Barber E, Hurley T, Matei D. A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. Cancers. 11. PMID 30965686 DOI: 10.3390/Cancers11040502  0.6
2018 Condello S, Sima LE, Ivan C, Cardenas H, Schiltz GE, Mishra RK, Matei D. Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche. Cancer Research. PMID 29510995 DOI: 10.1158/0008-5472.Can-17-2319  0.6
2017 Condello S, Nwani NG, Matei D. The hunt for elusive cancer stem cells. Oncotarget. PMID 28465496 DOI: 10.18632/Oncotarget.17443  0.6
2017 Sun H, Merrill D, An R, Turek J, Matei D, Nolte DD. Biodynamic imaging for phenotypic profiling of three-dimensional tissue culture. Journal of Biomedical Optics. 22: 16007. PMID 28301634 DOI: 10.1117/1.Jbo.22.1.016007  0.52
2017 Kanis MJ, Merrill D, Swetzig W, Cardenas H, Kim J, Matei D, Turek J, Nolte D. A pilot study evaluating biodynamic imaging (BDI) as a novel method in predicting response to chemotherapy in ovarian cancer Gynecologic Oncology. 145: 85. DOI: 10.1016/J.Ygyno.2017.03.199  0.52
2016 Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D, Cheng JX. Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell. PMID 28041894 DOI: 10.1016/J.Stem.2016.11.004  0.6
2016 Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. PMID 27062051 DOI: 10.1002/Cncr.29995  0.6
2016 Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, Huang T, Nephew KP. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. PMID 27041570 DOI: 10.1038/Onc.2016.75  0.6
2016 Merrill D, An R, Sun H, Yakubov B, Matei D, Turek J, Nolte D. Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts. Scientific Reports. 6: 18821. PMID 26732545 DOI: 10.1038/Srep18821  0.6
2016 Pepin JAT, Cardenas H, Moore C, Condello S, Guanglong J, Yunlong L, Matei D. Abstract 4486: Epigenetic vulnerabilities in ovarian cancer Cancer Research. 76: 4486-4486. DOI: 10.1158/1538-7445.Am2016-4486  0.6
2016 Qing Y, Condello S, Meyer KJ, Caperell-Grant A, Nephew KP, Matei D. Abstract 4024: Epigenetic priming potentiates immune checkpoints inhibitors in ovarian cancer Cancer Research. 76: 4024-4024. DOI: 10.1158/1538-7445.Am2016-4024  0.6
2016 Merrill D, Sun H, Matei D, Yakubov B, Turek J, Nolte D. Abstract 1541: Heterogeneous response to platinum in metastatic ovarian cancer detectable by biodynamic imaging Cancer Research. 76: 1541-1541. DOI: 10.1158/1538-7445.Am2016-1541  0.52
2015 Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. Plos One. 10: e0141279. PMID 26485143 DOI: 10.1371/Journal.Pone.0141279  0.6
2015 Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, ... ... Matei D, et al. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecologic Oncology. PMID 26050922 DOI: 10.1016/J.Ygyno.2015.05.040  0.6
2015 Lee J, Condello S, Yakubov B, Emerson R, Caperell-Grant A, Hitomi K, Xie J, Matei D. Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26041746 DOI: 10.1158/1078-0432.Ccr-15-0226  0.6
2015 Chang CL, Huang W, Jalal SI, Chan BD, Mahmood A, Shahda S, O'Neil BH, Matei DE, Savran CA. Circulating tumor cell detection using a parallel flow micro-aperture chip system. Lab On a Chip. 15: 1677-88. PMID 25687986 DOI: 10.1039/C5Lc00100E  0.6
2015 Reddy Ammakkanavar N, Matei D, Abonour R, Einhorn LH. High-dose chemotherapy for recurrent ovarian germ cell tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 226-7. PMID 25452440 DOI: 10.1200/Jco.2014.59.4325  0.6
2015 Tang J, Fang F, Miller DF, Pilrose JM, Matei D, Huang TH, Nephew KP. Global DNA methylation profiling technologies and the ovarian cancer methylome. Methods in Molecular Biology (Clifton, N.J.). 1238: 653-75. PMID 25421685 DOI: 10.1007/978-1-4939-1804-1_34  0.6
2015 Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, Matei D. β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 34: 2297-308. PMID 24954508 DOI: 10.1038/Onc.2014.178  0.6
2015 Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Matei D, Nephew KP. Abstract POSTER-THER-1421: Epigenetic targeting of ovarian cancer stem cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1421  0.6
2015 Condello S, Nagdas S, Morgan C, Turek J, Hurley T, Matei D. Abstract POSTER-BIOL-1309: Beta-catenin regulated ALDH1A1 is a target in ovarian cancer stem cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1309  0.6
2014 Nolte D, Turek J, Matei D, Childress M, An R, Merrill D. SU-E-J-31: Biodynamic Imaging of Cancer Tissue and Response to Chemotherapy. Medical Physics. 41: 161-162. PMID 28038218 DOI: 10.1118/1.4888082  0.52
2014 Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, Matei D. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics : Official Journal of the Dna Methylation Society. 9: 1461-72. PMID 25470663 DOI: 10.4161/15592294.2014.971608  0.6
2014 Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, Matei D, Turchi JJ, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6504-16. PMID 25316809 DOI: 10.1158/1078-0432.Ccr-14-1553  0.6
2014 Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5918-26. PMID 25261556 DOI: 10.1158/1078-0432.Ccr-14-1143  0.6
2014 Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, Matei D. Epigenetic targeting of ovarian cancer stem cells. Cancer Research. 74: 4922-36. PMID 25035395 DOI: 10.1158/0008-5472.Can-14-1022  0.6
2014 Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, Wulfridge P, Matei D, Nephew KP. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget. 5: 3579-89. PMID 25003579 DOI: 10.18632/Oncotarget.1961  0.6
2014 Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet. Oncology. 15: 852-61. PMID 24882434 DOI: 10.1016/S1470-2045(14)70228-1  0.6
2014 Deleon MC, Ammakkanavar NR, Matei D. Adjuvant therapy for endometrial cancer. Journal of Gynecologic Oncology. 25: 136-47. PMID 24761218 DOI: 10.3802/Jgo.2014.25.2.136  0.6
2014 Yakubov B, Chen L, Belkin AM, Zhang S, Chelladurai B, Zhang ZY, Matei D. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction. Plos One. 9: e89285. PMID 24586660 DOI: 10.1371/Journal.Pone.0089285  0.6
2014 Rosen LS, Gordon MS, Robert F, Matei DE. Endoglin for targeted cancer treatment. Current Oncology Reports. 16: 365. PMID 24445497 DOI: 10.1007/s11912-013-0365-x  0.6
2014 Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 33: 3619-33. PMID 23934194 DOI: 10.1038/Onc.2013.321  0.6
2014 Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Choy G, Azab M, Nephew K, Matei D. Abstract 2317: SGI-110 alters ovarian cancer stem cells to prevent recurrent and chemoresistant ovarian cancer Cancer Research. 74: 2317-2317. DOI: 10.1158/1538-7445.Am2014-2317  0.6
2014 Chang CL, Jalal SI, Huang W, Mahmood A, Matei DE, Savran CA. High-throughput immunomagnetic cell detection using a microaperture chip system Ieee Sensors Journal. 14: 3008-3013. DOI: 10.1109/Jsen.2014.2321167  0.6
2013 Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia (New York, N.Y.). 15: 609-19. PMID 23730209 DOI: 10.1593/Neo.121878  0.6
2013 Matei D, Brown J, Frazier L. Updates in the management of ovarian germ cell tumors. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. PMID 23714505 DOI: 10.1200/EdBook_AM.2013.33.e210  0.6
2013 Condello S, Cao L, Matei D. Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 3100-12. PMID 23640056 DOI: 10.1096/Fj.12-222620  0.6
2013 Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R, Braly P, Matei D, Morosky A, Dodion PF, Einstein MH, Haluska F. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. British Journal of Cancer. 108: 1021-6. PMID 23403817 DOI: 10.1038/Bjc.2013.59  0.6
2013 An R, Turek J, Matei DE, Nolte D. Live tissue viability and chemosensitivity assays using digital holographic motility contrast imaging. Applied Optics. 52: A300-9. PMID 23292406 DOI: 10.1364/Ao.52.00A300  0.52
2013 Condello S, Cao L, Matei D. Abstract C49: Tissue tranglutaminase regulates β-catenin signaling in ovarian cancer cells Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-C49  0.6
2012 Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, Perkins S, Ivan M, Matei D. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Molecular Cancer Therapeutics. 11: 1576-86. PMID 22700681 DOI: 10.1158/1535-7163.Mct-11-0961  0.6
2012 Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer Research. 72: 2197-205. PMID 22549947 DOI: 10.1158/0008-5472.Can-11-3909  0.6
2012 Alley WR, Vasseur JA, Goetz JA, Svoboda M, Mann BF, Matei DE, Menning N, Hussein A, Mechref Y, Novotny MV. N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. Journal of Proteome Research. 11: 2282-300. PMID 22304416 DOI: 10.1021/Pr201070K  0.6
2012 Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 31: 2521-34. PMID 21963846 DOI: 10.1038/Onc.2011.429  0.6
2012 Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treatment Reviews. 38: 272-83. PMID 21764518 DOI: 10.1016/J.Ctrv.2011.06.004  0.6
2012 Schmitt J, Thomas M, Caperell-Grant A, Chelladurai B, Cao L, Mehtala J, Perkins S, Wei A, Matei D. Abstract 3439: Tissue tranglutaminase (TG2) targeting by multifunctional field responsive gold nanoparticles Cancer Research. 72: 3439-3439. DOI: 10.1158/1538-7445.Am2012-3439  0.6
2012 Chang CL, Savran CA, Jalal S, Matei DE. Micro-aperture chip system for high-throughput immunomagnetic cell detection Proceedings of Ieee Sensors. DOI: 10.1109/ICSENS.2012.6411336  0.6
2012 Matei DE, Schilder JM, Michael H. Germ Cell Tumors of the Ovary Textbook of Uncommon Cancer. 519-530. DOI: 10.1002/9781118464557.ch37  0.6
2011 Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecologic Oncology. 123: 499-504. PMID 21955480 DOI: 10.1016/J.Ygyno.2011.08.033  0.6
2011 Khanna M, Chelladurai B, Gavini A, Li L, Shao M, Courtney D, Turchi JJ, Matei D, Meroueh S. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Molecular Cancer Therapeutics. 10: 626-36. PMID 21330459 DOI: 10.1158/1535-7163.Mct-10-0912  0.6
2011 Shao M, Rossi S, Chelladurai B, Shimizu M, Ntukogu O, Ivan M, Calin GA, Matei D. PDGF induced microRNA alterations in cancer cells. Nucleic Acids Research. 39: 4035-47. PMID 21266476 DOI: 10.1093/Nar/Gkq1305  0.6
2011 Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 69-75. PMID 21098323 DOI: 10.1200/Jco.2009.26.7856  0.6
2010 Balch C, Matei DE, Huang TH, Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2: 419-47. PMID 22121902 DOI: 10.2217/Epi.10.19  0.6
2010 Ivan M, Matei D. Blockade of FGF signaling: therapeutic promise for ovarian cancer. Cancer Biology & Therapy. 10: 505-8. PMID 20686363 DOI: 10.4161/Cbt.10.5.13023  0.6
2010 Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer. 116: 5251-60. PMID 20665885 DOI: 10.1002/Cncr.25487  0.6
2010 Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 116: 4043-53. PMID 20564122 DOI: 10.1002/Cncr.25204  0.6
2010 De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 149-53. PMID 19917861 DOI: 10.1200/Jco.2009.24.1455  0.6
2010 Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecologic Oncology. 116: 195-201. PMID 19854495 DOI: 10.1016/J.Ygyno.2009.09.043  0.6
2009 Gayathri S, Badve S, Matei D. Breast mass in a patient with ovarian cancer: a case report. The Journal of Reproductive Medicine. 54: 639-44. PMID 20677485  0.6
2009 Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Research. 69: 9192-201. PMID 19951993 DOI: 10.1158/0008-5472.Can-09-1257  0.6
2009 Strother R, Matei D. Pegylated liposomal doxorubicin in ovarian cancer. Therapeutics and Clinical Risk Management. 5: 639-50. PMID 19707541 DOI: 10.2147/Tcrm.S5148  0.6
2009 Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, Champion VL, Williams SD. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4142-9. PMID 19636015 DOI: 10.1200/Jco.2008.20.9189  0.6
2009 Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecologic Oncology. 115: 90-6. PMID 19577796 DOI: 10.1016/J.Ygyno.2009.05.042  0.6
2009 Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 150: 4003-11. PMID 19574400 DOI: 10.1210/En.2009-0404  0.6
2009 Satpathy M, Shao M, Emerson R, Donner DB, Matei D. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. The Journal of Biological Chemistry. 284: 15390-9. PMID 19324884 DOI: 10.1074/Jbc.M808331200  0.6
2008 Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, Matei DE, Koch KM, Alvarez RD. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecologic Oncology. 111: 95-101. PMID 18692224 DOI: 10.1016/J.Ygyno.2008.07.001  0.6
2008 Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 29: 1893-900. PMID 18667446 DOI: 10.1093/Carcin/Bgn158  0.6
2008 Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer. 113: 723-32. PMID 18618737 DOI: 10.1002/Cncr.23605  0.6
2008 Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Research. 68: 4311-20. PMID 18519691 DOI: 10.1158/0008-5472.Can-08-0364  0.6
2008 Schmitt J, Matei D. Platelet-derived growth factor pathway inhibitors in ovarian cancer Clinical Ovarian Cancer. 1: 120-126. DOI: 10.3816/Coc.2008.N.013  0.6
2007 Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology & Therapy. 6: 1951-9. PMID 18075302 DOI: 10.4161/Cbt.6.12.4976  0.6
2007 Matei D. Novel agents in ovarian cancer. Expert Opinion On Investigational Drugs. 16: 1227-39. PMID 17685871 DOI: 10.1517/13543784.16.8.1227  0.6
2007 Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Research. 67: 7194-202. PMID 17671187 DOI: 10.1158/0008-5472.Can-07-0307  0.6
2007 Matei D, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB. The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. The Journal of Biological Chemistry. 282: 445-53. PMID 17079230 DOI: 10.1074/Jbc.M607012200  0.6
2007 Matei D, Kelich S, Cao L, Menning N, Emerson R, Rao J, Sledge G. Induction of VEGF secretion in ovarian cancer by PDGF BB Journal of Clinical Oncology. 25: 5557-5557. DOI: 10.1200/Jco.2007.25.18_Suppl.5557  0.6
2006 Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4324-32. PMID 16896006 DOI: 10.1200/Jco.2005.05.4221  0.6
2006 Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 25: 2060-9. PMID 16331269 DOI: 10.1038/Sj.Onc.1209232  0.6
2006 Matei D. Neuroprotective effects of vitamin E Women's Oncology Review. 6: 97-98. DOI: 10.1080/14733400600615691  0.6
2004 Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 681-90. PMID 14760091 DOI: 10.1158/1078-0432.Ccr-0754-03  0.6
2002 Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Research. 62: 5358-64. PMID 12235007  0.6
2002 Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD. Gene expression in epithelial ovarian carcinoma. Oncogene. 21: 6289-98. PMID 12214269 DOI: 10.1038/Sj.Onc.1205785  0.6
2001 Matei D, Brenner B, Marder VJ. Acquired thrombophilic syndromes Blood Reviews. 15: 31-48. PMID 11333137 DOI: 10.1054/Blre.2001.0148  0.6
1999 Madajewicz S, Matei D, Hentschel P, Kudelka A, Abel W, Fiore JJ, DaCosta NA, Pendyala L. Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid Cancer Investigation. 17: 463-467. PMID 10518189 DOI: 10.3109/07357909909032854  0.6
1995 Matei D, Hagag N, Madajewicz S, Chowhan N, Hentschel P, Avvento L, Burns P, Fiore J, Lipera W, Zarrabi H. Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma Cancer. 76: 1330-1335. PMID 8620405 DOI: 10.1002/1097-0142(19951015)76:8<1330::AID-CNCR2820760806>3.0.CO;2-2  0.6
Show low-probability matches.